Recursion raises $200 M in follow‑on offering and receives $10 M Sanofi milestone
Recursion Pharmaceuticals announced a $200 million common‑stock offering that lifts its cash balance to $561 million and extends its cash runway to 2029. On the same day Sanofi exercised an option on the first development candidate from their collaboration, triggering a $10 million milestone payment and bringing total payments from Sanofi to $144 million. The optioned oral small‑molecule candidate is slated to start Phase 1 trials in 2027, and Recursion remains eligible for more than $300 million in additional milestones and royalties.
Why it matters
The financing gives Recursion enough cash to fund operations through 2029, reducing short‑term funding risk (the company says). The $10 million milestone will be recognized as revenue in Q3 2026, adding immediate earnings and further aligning the partnership with Sanofi.
Key facts
- 1Recursion raised $200 million via an underwritten common‑stock offering. tradingview.com
- 2The offering increased cash on hand to $561 million and extends the cash runway into 2029. investing.com
- 3Sanofi optioned the first development candidate, triggering a US$10 million milestone payment. securities.io
- 4The milestone brings total upfront and milestone payments received from Sanofi to $144 million. securities.io
- 5Recursion may earn more than $300 million in additional milestones and royalties if the candidate succeeds. tradingview.com
- 6The optioned oral small‑molecule candidate is expected to enter Phase 1 clinical trials in 2027. stocktitan.net
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.